MVP Health Care, a regional not-for-profit health insurer serving the Northeast, has partnered with Renalytix Plc to expand access to innovative kidney disease testing for patients with type 2 diabetes and chronic kidney disease. The collaboration, announced last Thursday, introduces the FDA-approved kidneyintelX.dkd test across MVP's provider network to enable earlier identification of patients at higher risk for progressive kidney function decline.
Partnership Aims to Transform Kidney Care Management
The partnership combines Renalytix's artificial intelligence-enabled diagnostic technology with MVP's commitment to equitable healthcare delivery. By implementing the kidneyintelX.dkd test, clinicians can better target resources, therapeutic options, and care plans to patients most likely to benefit, potentially slowing disease progression and improving outcomes related to cardiovascular and metabolic conditions.
"At MVP Health Care, we are committed to delivering innovative, affordable solutions that improve access to care and support better health for our members," said Dr. Richard Dal Col, MVP Health Care's President. "This partnership with Renalytix reflects our mission to empower both providers and patients with the tools they need to make informed, proactive decisions about their health care journey. For our customers living with type 2 diabetes and CKD, this means earlier insights, more personalized support, and a better path forward."
Broad Access Across New York
The kidneyintelX.dkd test will be available to all MVP customers in New York, including those with Medicare or Medicaid coverage. The test has received recommendation from KDIGO, the international clinical guideline organization for kidney disease, lending additional clinical credibility to the diagnostic tool.
James McCullough, CEO of Renalytix, emphasized the partnership's potential impact on addressing the chronic kidney disease epidemic. "Forward-thinking in its approach, MVP Health Care is bringing together the right partners to address the growing and costly CKD epidemic," McCullough said. "Where kidneyintelX.dkd is in use, we are seeing measurable improvements in patient outcomes and quality metrics, including HEDIS measures for blood pressure and HbA1c control in high-risk populations."
Technology and Clinical Impact
Renalytix operates as an artificial intelligence-enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease. The company has secured both FDA approval and Medicare reimbursement for kidneyintelX.dkd, which is now commercially available in the United States.
The partnership represents a strategic approach to precision medicine in kidney care, targeting patients with type 2 diabetes and chronic kidney disease who may benefit most from early intervention strategies. By identifying high-risk patients earlier in the disease progression, healthcare providers can implement more aggressive treatment protocols and monitoring strategies to preserve kidney function and prevent complications.
